Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Sharsti L. Sandall, Marsha Mason, Devra Olson, Rebecca Mazahreh, Tom Pires, Disha Sahetya, Lori Westendorf, Chris Leiske, Brian Schimpf, Liem Nguyen, Madhu Katepalli, Esther Trueblood, Christopher Hale, Albina Nesterova, Jason Wall and Timothy S. Lewis | ||||||||||||
Title | SGN-CD228A: A novel humanized anti-CD228 antibody-drug conjugate for the treatment of solid tumors | ||||||||||||
|
|||||||||||||
URL | https://cancerres.aacrjournals.org/content/79/13_Supplement/2688 | ||||||||||||
Abstract Text | Cancer Res 2019;79(13 Suppl):Abstract nr 2688 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
SGN-CD228A | SGN-CD228A | 0 | 1 |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SGN-CD228A | SGNCD228A|SGN CD228A | SGN-CD228A is an antibody-drug conjugate comprising a CD228 monoclonal antibody linked to eight molecules of the anti-microtubule compound MMAE, which delivers the cytotoxic agent to CD228-expressing tumor cells, potentially resulting in delayed tumor growth (Cancer Res 2019;79(13 Suppl):Abstract nr 2688). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|